Answers are grounded in this paper and cite their sources.
ABSTRACT 73% of women dying from breast cancer (BC) come from low‐ or middle‐income countries. These countries often do not have national mammography screening programmes. A less resource‐demanding option is screening through clinical breast examination (CBE). As limited evidence exists for its effectiveness, two CBE trials have been conducted in India to assess efficacy with different designs and results. This study aims to model the natural history of BC and the performance of CBE using data from both trials to estimate the long‐term effects of CBE and alternative screening scenarios. We used the well‐established microsimulation model MISCAN‐Fadia and utilized region‐specific incidence, trial‐specific inputs (such as screening interval, screening ages, attendance, and treatment regimens) to construct trial‐specific models. We reported outcomes for both Trivandrum and Mumbai models with respectively 14 and 20 years follow‐up time, as well as lifetime follow‐up. The stage distribution in both trials was accurately reproduced by the models. Our models estimated BC mortality reductions between 5% and 6% for the Indian CBE trials, which were higher than reported by the CBE Trivandrum trial and lower than the Mumbai trial. When assuming 100% attendance with triennial screening between age 30–69 and a lifetime follow‐up, model results showed a BC mortality reduction of 12%. Women in resource‐limited countries may benefit from CBE screening, which given resources should not be seen as second‐best. Screening with CBE in a broad age range of 30–69 can lead to reductions in BC mortality.
No takes yet. Share an insight, caveat, or question.
Chootipongchaivat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: